Business
AI suggests Australia may have backed a COVID-19 vaccine winner – The Australian Financial Review
Even the COVID-19 vaccines in phase three clinical trials have only a 20 per cent chance of success, an Australian AI healthcare data company says.
Some of the positive factors supporting the vaccine were the number of trial locations (approximately 20), trial participants (more than 12,000) and its randomised design. The chance of the trial succeeding could be improved by increasing the number of countries where the trial operates.
Ms Gallaher, who has spent 30 years in the biotech and pharmaceutical industry, and has also taken part in clinical trials, hoped the research would help governments and investors around the globe to pick which…
-
Noosa News18 hours agoGippsland vegetable farm accused of underpaying migrant workers
-
General19 hours agoFour escape injury after jumping from three-storey unit on fire in Newcastle
-
General16 hours agoIncreased police powers begin at Adelaide Oval Ashes Test following Bondi attacks
-
General24 hours agoDe-escalation skills, not guards, needed in Tasmanian hospitals, nurses’ union says